On October 27, 2020 Celsius Holdings, Inc., (Nasdaq: CELH), maker of the leading global fitness drink, CELSIUS, reported that it will release financial results for the third quarter ended September 30, 2020 on Thursday, November 12, 2020, before the market open (Press release, Celsius Therapeutics, OCT 27, 2020, View Source [SID1234569164]). Management will then host a conference call that same day at 10:00 a.m. Eastern Time to discuss the results with the investment community.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, please call one of the following telephone numbers at least 10 minutes before the start of the call:

The conference may also be accessed by going to: View Source;passcode=13668240&h=true&info=company&r=true&B=6, for the live audio webcast of the call, which will subsequently be available for replay.

On October 27, 2020 Syntrix Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class product candidates focused on emerging immune control mechanisms in oncology indications, reported it completed initial SX-682 dosing in Phase 1/2 trials in myelodysplastic syndromes (MDS) and metastatic melanoma (Press release, Syntrix, OCT 27, 2020, View Source [SID1234569162]). The drug was well tolerated and absorbed with excellent dose-proportional drug levels in blood. The trials are being conducted at the Moffitt Cancer Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, Mayo Clinic and the University of Rochester.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

There is a major need for new cancer treatments targeting novel immune control mechanisms in cancer since existing immunotherapies induce a durable response in only a small percentage of patients. SX-682 is the company’s lead drug from its tumor-microenvironment (TME) discovery platform targeting key molecular pathways cancer uses to shield itself from immune attack. High-profile scientific publications from major cancer centers report SX-682 potently eradicates cancer and extends survival: National Cancer Institute (JCI Insight, J Immunother Cancer), Fred Hutchinson Cancer Research Institute (JCI Insight), and MD Anderson (Nature and Cancer Cell).

Based on these promising results, additional Phase 1/2 trials are now also opening for SX-682 in pancreatic cancer at the University of Rochester, in colorectal cancer at the MD Anderson Cancer Center, and in advanced tumors including breast and head and neck cancers at the National Institutes of Health Clinical Center.

"The CXCR1/2 pathway blocked by SX-682 suppresses anti-tumor immunity," said John Zebala, MD, PhD, president at Syntrix. "Patients with low CXCR1/2 activity survive significantly longer compared to patients with high activity. We are hopeful the same effect can be achieved by pharmacologically blocking the pathway with SX-682. We believe the breadth of the SX-682 clinical program positions it for major read-outs."

ABOUT SX-682: SX-682 is a clinical-stage oral allosteric small-molecule inhibitor of CXCR1 and CXCR2 (CXCR1/2). CXCR1/2 is a "master switch" of the immunosuppressive tumor microenvironment. In patients there is an inverse correlation between CXCR1/2 activation and survival. SX-682 has been validated in major tumor models where it exhibits mono-agent activity, extends survival, blocks metastasis, activates infiltration and killing by immune effector cells, and enhances cancer checkpoint and cell therapies.

On October 27, 2020 Genome & Company (KONEX: 314130), a global pioneer company of microbiome therapeutics, reported that initiated clinical trials of GEN-001, an anti-cancer microbiome therapeutic (NCT04601402) (Press release, Genome & Company, OCT 27, 2020, View Source;company-announces-first-patient-dosed-in-phase-11b-study-of-gen-001-an-immuno-oncology-microbiome-therapeutic-in-combination-with-avelumab-301158564.html [SID1234569161]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

GEN-001 is an oral microbiome therapeutic candidate of Genome & Company. In this clinical trial, it will be administered to cancer patients by combining an immune checkpoint inhibitor for the first time among Asian microbiome development companies.

The phase 1 study aims to determine the RP2D (recommended Phase 2 dose) of GEN-001 in combination with BAVENCIO (avelumab). Avelumab is an anti-PD-L1 checkpoint inhibitor co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany and Pfizer Inc. In the phase 1b study, the safety and preliminary efficacy of the combination therapy at the RP2D of GEN-001 in combination with BAVENCIO for patients with specific solid tumors will be investigated.

A total of three clinical sites including OHSU Knight Cancer Institute located in Portland, Oregon will complete the dose escalation cohort within the first half of 2021. The OHSU Knight Cancer Institute is a globally renowned cancer center and one of the 51 National Cancer Institute (NCI) designated Comprehensive Cancer Centers in the U.S. Amid harsh conditions due to COVID-19, close collaboration among OHSU, contract research organization and Genome & Company enabled this clinical trial to initiate only after six months since its FDA IND clearance.

"We are pleased to offer our patients access to a new clinical trial of the drug GEN-001 in combination with avelumab," said Shivaani Kummar, M.D., head of the division of hematology and medical oncology in the OHSU School of Medicine, and co-director of the OHSU Knight Cancer Institute Center for Experimental Therapeutics. "Our goal is to learn more about whether this combination therapy will be effective in overcoming acquired resistance to anti-PD-(L)1 therapy in patients with advanced solid tumors whose disease has progressed on prior anti-PD-(L)1 therapy."

Dr. Jisoo Pae, CEO of Genome & Company stated, "The study outcome of GEN001-101 is expected to demonstrate preliminary efficacy of GEN-001 in various cancers. We hope to see clinically meaningful results fairly soon that would allow us to continue to progress GEN-001 through clinical trials, with the potential to eventually become an alternative therapeutic option in the immuno-oncology market."

In December 2019, Genome & Company inked a Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate the safety, tolerability, biological and clinical activities of GEN-001 therapy in combination with avelumab, a human anti-PD-L1 therapy, in multiple cancer indications. Under the terms of this agreement, Genome & Company will be the sponsor of the study, and Merck KGaA, Darmstadt, Germary and Pfizer will supply avelumab for the phase 1/1b clinical trial.

BAVENCIO is a trademark of Merck KGaA, Darmstadt, Germany.

Avelumab Approved Indications

Avelumab (BAVENCIO) is indicated in the US for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy. BAVENCIO is also indicated for the treatment of patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Avelumab in combination with axitinib is approved in the US for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

In the US, the FDA granted accelerated approval for BAVENCIO for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

Avelumab Important Safety Information from the US FDA-Approved Label

The warnings and precautions for avelumab (BAVENCIO) include immune-mediated adverse reactions (such as pneumonitis and hepatitis [including fatal cases], colitis, endocrinopathies, nephritis, and other immune-mediated adverse reactions as a single agent or in combination with axitinib [which can be severe and have included fatal cases]), infusion-related reactions, hepatotoxicity in combination with axitinib, major adverse cardiovascular events (MACE) in combination with axitinib [which can be severe and have included fatal cases], and embryo-fetal toxicity.

Common adverse reactions (reported in at least 20% of patients) in patients treated with BAVENCIO monotherapy include fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reaction peripheral edema, decreased appetite, urinary tract infection and rash. Common adverse reactions (reported in at least 20% of patients) in patients receiving BAVENCIO in combination with axitinib include diarrhea, fatigue, hypertension, musculoskeletal pain, nausea, mucositis, palmar-plantar erythrodysesthesia, dysphonia, decreased appetite, hypothyroidism, rash, hepatotoxicity, cough, dyspnea, abdominal pain and headache. Grade 3-4 hematology laboratory value abnormalities reported in at least 10% of patients with Merkel cell carcinoma treated with BAVENCIO monotherapy include lymphopenia; in patients receiving BAVENCIO in combination with axitinib, grade 3-4 clinical chemistry abnormalities include blood triglyceride increased and lipase increased.

On October 27, 2020 Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, reported that Palmetto GBA, a Medicare Administrative Contractor (MAC), has established coverage of the StrataNGS test for patients with advanced stages (III or IV), recurrent, relapsed, refractory, and/or metastatic solid tumors (Press release, Strata Oncology, OCT 27, 2020, View Source [SID1234569159]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

StrataNGS is a comprehensive genomic profiling (CGP) test that features leading performance on small tumor tissue samples. The 429-gene assay is performed on co-isolated RNA and DNA. Single-/multi-nucleotide variants (SNVs), short insertions and deletions (indels), copy number alterations (CNAs; amplifications and deep deletions), microsatellite instability (MSI) status, gene fusions, and tumor mutation burden (TMB) are assessed simultaneously.

A recent study presented at the 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) showed that the performance of StrataNGS on small tumor tissue samples may enable access to testing for more than double the number of patients compared to other leading comprehensive genomic profiling (CGP) tests. The results from an analysis of data collected in the Strata Trial demonstrated that only 43 percent of >20,000 consecutive tumor tissue samples received for CGP met tissue surface area requirements for leading commercial hybrid-capture-CGP tests. StrataNGS, a PCR-CGP test, delivered reportable results in 93 percent of all samples received.

"Medicare coverage of StrataNGS is an important milestone toward enabling broader access to comprehensive genomic profiling for patients with cancer," said Dan Rhodes, Ph.D., co-founder and CEO of Strata Oncology. "Tumor tissue availability is a major barrier to test access. With industry-low tumor tissue requirements, StrataNGS expands the number of patients that can receive tissue-based molecular profiling and potentially benefit from biomarker-guided targeted and immunotherapies."

StrataNGS has been available to patients as part of the Strata Trial, an observational trial conducted by Strata Oncology at over 125 hospitals nationwide. The company will continue to focus on its health system network before pursuing a broader commercial launch in 2021.

About StrataNGS
StrataNGS is a comprehensive genomic profiling (CGP) test that features leading performance on small tumor tissue samples (>0.5mm2 surface area). The 429-gene assay is performed on co-isolated RNA and DNA. Single-/multi-nucleotide variants (SNVs), short insertions and deletions (indels), copy number alterations (CNAs; amplifications and deep deletions), microsatellite instability (MSI) status, gene fusions, and tumor mutation burden (TMB) are assessed simultaneously.

On October 27, 2020 Unum Group (NYSE: UNM) reported net income of $231.1 million ($1.13 per diluted common share) for the third quarter of 2020, compared to net income of $242.0 million ($1.16 per diluted common share) for the third quarter of 2019 (Press release, Unum Therapeutics, OCT 27, 2020, View Source [SID1234569158]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Included in net income for the third quarter of 2020 are after-tax costs related to an organizational design update of $18.6 million ($0.09 per diluted common share), as well as a net after-tax realized investment gain on the Company’s investment portfolio of $3.8 million ($0.01 per diluted common share). Included in net income for the third quarter of 2019 are after-tax costs related to the early retirement of debt of $19.9 million ($0.10 per diluted common share), as well as a net after-tax realized investment loss on the Company’s investment portfolio of $20.8 million ($0.10 per diluted common share). Excluding the items above, after-tax adjusted operating income was $245.9 million ($1.21 per diluted common share) in the third quarter of 2020, compared to $282.7 million ($1.36 per diluted common share) in the third quarter of 2019.

"Financial performance remained solid in the third quarter, despite pressure from elevated mortality rates and unemployment levels," said Richard P. McKenney, president and chief executive officer. "Our team continues to deliver solid operational performance, adapting to best serve our customers in this extraordinary time. This environment reinforces the fundamental purpose for what we do in protecting employees and their families in time of need. We continue to be well-positioned to benefit from better business conditions as the economy improves and will continue to effectively manage through today’s challenges."

RESULTS BY SEGMENT

We measure and analyze our segment performance on the basis of "adjusted operating income" or "adjusted operating loss," which differ from income before income tax as presented in our consolidated statements of income due to the exclusion of net realized investment gains and losses and certain other items. These performance measures are in accordance with GAAP guidance for segment reporting, but they should not be viewed as a substitute for income before income tax or net income.

Unum US Segment

Unum US reported adjusted operating income of $188.2 million in the third quarter of 2020, a decrease of 28.0 percent from $261.4 million in the third quarter of 2019. Premium income for the segment decreased 1.2 percent to $1,483.4 million in the third quarter of 2020, compared to premium income of $1,501.9 million in the third quarter of 2019. Net investment income for the segment increased 3.5 percent to $190.7 million in the third quarter of 2020, compared to $184.2 million in the third quarter of 2019.

Within the Unum US operating segment, the group disability line of business reported a 12.0 percent decrease in adjusted operating income to $73.0 million in the third quarter of 2020, compared to $83.0 million in the third quarter of 2019. Premium income for the group disability line of business was $646.7 million in the third quarter of 2020, which was generally consistent with the $648.0 million in the third quarter of 2019. Net investment income increased 5.9 percent to $105.4 million in the third quarter of 2020, compared to $99.5 million in the third quarter of 2019, driven by higher miscellaneous investment income, partially offset by a lower yield on invested assets. The benefit ratio of 74.1 percent for the third quarter of 2020 was generally consistent with the 74.2 percent in the third quarter of 2019, due to higher claim recoveries in our group long-term disability product line, mostly offset by higher claims incidence in the short term disability product line. Group long-term disability sales were $29.8 million in the third quarter of 2020, an increase of 25.2 percent from $23.8 million in the third quarter of 2019. Group short-term disability sales were $15.2 million in the third quarter of 2020, a decrease of 25.9 percent from $20.5 million in the third quarter of 2019. Persistency in the group long-term disability product line was 90.3 percent for the first nine months of 2020, compared to 90.7 percent for the first nine months of 2019. Persistency in the group short-term disability product line was 87.5 percent for the first nine months of 2020, compared to 89.9 percent for the first nine months of 2019.

The group life and accidental death and dismemberment line of business reported adjusted operating income of $13.9 million in the third quarter of 2020, a decrease of 79.7 percent from $68.4 million in the third quarter of 2019. Premium income for this line of business decreased 2.3 percent to $446.0 million in the third quarter of 2020, compared to $456.5 million in the third quarter of 2019, driven primarily by lower year-to-date sales and persistency. Net investment income decreased 6.7 percent to $25.2 million in the third quarter of 2020, compared to $27.0 million in the third quarter of 2019, due primarily to decline in both the yield and level of invested assets, partially offset by higher miscellaneous investment income. The benefit ratio in the third quarter of 2020 was 83.5 percent, compared to 72.0 percent in the third quarter of 2019, due primarily to higher claims incidence in the group life product line, likely resulting from the impacts of COVID-19. Sales of group life and accidental death and dismemberment products increased 1.3 percent in the third quarter of 2020 to $31.3 million, compared to $30.9 million in the third quarter of 2019. Persistency in the group life product line was 88.6 percent for the first nine months of 2020, compared to 90.8 percent for the first nine months of 2019. Persistency in the accidental death and dismemberment product line was 87.8 percent for the first nine months of 2020, compared to 90.1 percent for the first nine months of 2019.

The supplemental and voluntary line of business reported a decrease of 7.9 percent in adjusted operating income to $101.3 million in the third quarter of 2020, compared to $110.0 million in the third quarter of 2019. Premium income for the supplemental and voluntary line of business decreased 1.7 percent to $390.7 million in the third quarter of 2020, compared to $397.4 million in the third quarter of 2019, with declines in the voluntary benefits and dental and vision product lines, partially offset by growth in the individual disability product line. Net investment income increased 4.2 percent to $60.1 million in the third quarter of 2020, compared to $57.7 million in the third quarter of 2019, due to a higher miscellaneous investment income, partially offset by a decline in the yield on invested assets. The benefit ratio for the individual disability product line was 48.6 percent for the third quarter of 2020, compared to 49.5 percent for the third quarter of 2019, due to favorable claim recoveries. The benefit ratio for the voluntary benefits product line was 45.6 percent in the third quarter of 2020, compared to 44.2 percent for the third quarter of 2019, due primarily to higher claims incidence in the life product line, likely resulting from the impacts of COVID-19. The benefit ratio for the dental and vision product line was 76.8 percent for the third quarter of 2020, compared to 74.0 percent for the third quarter of 2019, due primarily to higher claims incidence. Relative to the third quarter of 2019, sales in the individual disability product line declined 37.3 percent in the third quarter of 2020 to $17.0 million. Sales in the voluntary benefits product line declined 35.8 percent in the third quarter of 2020 to $29.9 million. Sales in the dental and vision product line totaled $8.5 million for the third quarter of 2020, a decrease of 33.1 percent compared to the third quarter of 2019. Persistency in the individual disability product line was 89.8 percent for the first nine months of 2020, compared to 90.1 percent for the first nine months of 2019. Persistency in the voluntary benefits product line was 72.7 percent for the first nine months of 2020, compared to 72.5 percent for the first nine months of 2019. Persistency in the dental and vision product line was 82.4 percent for the first nine months of 2020, compared to 84.1 percent for the first nine months of 2019.

Unum International

The Unum International segment reported adjusted operating income of $21.4 million in the third quarter of 2020, a decrease of 11.6 percent from $24.2 million in the third quarter of 2019. Premium income increased 8.6 percent to $165.4 million in the third quarter of 2020, compared to $152.3 million in the third quarter of 2019. Net investment income increased 8.2 percent to $26.3 million in the third quarter of 2020, compared to $24.3 million in the third quarter of 2019. Sales decreased 9.7 percent to $17.7 million in the third quarter of 2020, compared to $19.6 million in the third quarter of 2019.

The Unum UK line of business reported adjusted operating income, in local currency, of £15.2 million in the third quarter of 2020, a decrease of 18.7 percent from £18.7 million in the third quarter of 2019. Premium income was £112.1 million in the third quarter of 2020, an increase of 2.8 percent from £109.0 million in the third quarter of 2019, driven by growth in the in-force block and the impact of rate increases in the group long-term disability product line. Net investment income was £18.9 million in the third quarter of 2020, an increase of 3.3 percent from £18.3 million in the third quarter of 2019, due to higher investment income from inflation index-linked bonds, partially offset by a lower yield on fixed-rate bonds. The benefit ratio in the third quarter of 2020 was 77.1 percent, compared to 73.4 percent in the third quarter of 2019, due to lower claim resolutions in the group long-term disability product line resulting from the continued disruption in claim processes related to COVID-19 and overall higher claims incidence. Sales decreased 20.7 percent to £10.7 million in the third quarter of 2020, compared to £13.5 million in the third quarter of 2019. Persistency in the group long-term disability product line was 87.2 percent for the first nine months of 2020, compared to 88.9 percent for the first nine months of 2019. Persistency in the group life product line was 81.0 percent for the first nine months of 2020, compared to 88.3 percent for the first nine months of 2019. Persistency in the supplemental product line was 90.3 percent for the first nine months of 2020, compared to 92.3 percent for the first nine months of 2019.

Colonial Life Segment

Colonial Life reported a 5.7 percent increase in adjusted operating income to $92.2 million in the third quarter of 2020, compared to $87.2 million in the third quarter of 2019. Premium income was $419.9 million in the third quarter of 2020, which was consistent with the $419.9 million in the third quarter of 2019. Net investment income increased 18.4 percent to $43.7 million in the third quarter of 2020 compared to the $36.9 million in the third quarter of 2019, due to higher miscellaneous investment income and an increase in the level of invested assets, partially offset by a decline in the yield on invested assets. The benefit ratio was 52.2 percent in the third quarter of 2020, compared to 51.4 percent in the third quarter of 2019, with unfavorable experience in the life product line, likely resulting from the impacts of COVID-19, partially offset by favorable experience in both the cancer and critical illness and accident, sickness, and disability lines of business.

Sales decreased 27.6 percent to $87.3 million in the third quarter of 2020, compared to $120.6 million in the third quarter of 2019. Persistency in Colonial Life was 77.6 percent for the first nine months of 2020, compared to 77.2 percent for the first nine months of 2019.

Closed Block Segment

The Closed Block segment reported adjusted operating income of $70.8 million in the third quarter of 2020, an increase of 163.2 percent from $26.9 million in the third quarter of 2019. Premium income for this segment declined 3.0 percent in the third quarter of 2020, compared to the third quarter of 2019, due to continued policy terminations and maturities in the individual disability line of business, partially offset by premium rate increases on certain in-force business in the long-term care line of business. Net investment income increased 1.1 percent to $351.2 million in the third quarter of 2020, compared to $347.3 million in the third quarter of 2019, due primarily to improved net asset values on our private equity partnerships and a higher level of invested assets, partially offset by a decrease in the yield on invested assets.

The interest adjusted loss ratio for the long-term care line of business was 67.4 percent in the third quarter of 2020, compared to an interest adjusted loss ratio of 89.8 percent in the third quarter of 2019, driven primarily by higher claimant mortality. The interest adjusted loss ratio for long-term care for the rolling twelve months ended September 30, 2020 was 75.6 percent which is below our long-term expected range. The interest adjusted loss ratio for the individual disability line of business was 86.6 percent in the third quarter of 2020, compared to 79.0 percent in the third quarter of 2019, driven by overall unfavorable claims activity.

Corporate Segment

The Corporate segment reported an adjusted operating loss of $54.1 million in the third quarter of 2020, which excludes the costs related to an organizational design update of $23.3 million compared to an adjusted operating loss of $48.9 million in the third quarter of 2019, which excludes the cost related to the early retirement of debt of $25.2 million.

OTHER INFORMATION

Shares Outstanding

The Company’s weighted average number of shares outstanding, assuming dilution, was 203.9 million for the third quarter of 2020, compared to 208.1 million for the third quarter of 2019. Shares outstanding totaled 203.6 million at September 30, 2020. The Company did not repurchase shares during the first nine months of 2020 and will not repurchase shares for the remainder of 2020.

Capital Management

At September 30, 2020, the weighted average risk-based capital ratio for the Company’s traditional U.S. insurance companies was approximately 380 percent, and cash and marketable securities in the holding companies equaled $1,178 million.

The Company intends to continue to pay its common stock dividend at the current rate.

Book Value

Book value per common share as of September 30, 2020 was $53.50, compared to $46.70 at September 30, 2019.

Outlook

As announced previously, due to the uncertain economic environment caused by the COVID-19 pandemic, the Company is suspending its financial guidance for the remainder of 2020.

NON-GAAP FINANCIAL MEASURES

We analyze our performance using non-GAAP financial measures. A non-GAAP financial measure is a numerical measure of a company’s performance, financial position, or cash flows that excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. The non-GAAP financial measure of "after-tax adjusted operating income" differs from net income as presented in our consolidated operating results and income statements prepared in accordance with GAAP due to the exclusion of net realized investment gains and losses and certain other items as specified in the reconciliations in the Financial Highlights section below. We believe after-tax adjusted operating income is a better performance measure and better indicator of the profitability and underlying trends in our business.

Realized investment gains or losses depend on market conditions and do not necessarily relate to decisions regarding the underlying business of our segments. Our investment focus is on investment income to support our insurance liabilities as opposed to the generation of realized investment gains or losses. Although we may experience realized investment gains or losses which will affect future earnings levels, a long-term focus is necessary to maintain profitability over the life of the business since our underlying business is long-term in nature, and we need to earn the interest rates assumed in calculating our liabilities.

We may at other times exclude certain other items from our discussion of financial ratios and metrics in order to enhance the understanding and comparability of our operational performance and the underlying fundamentals. We exclude these items as we believe them to be infrequent or unusual in nature, but this exclusion is not an indication that similar items may not recur and does not replace net income or net loss as a measure of our overall profitability.

CONFERENCE CALL INFORMATION

Members of Unum Group senior management will host a conference call on Wednesday, October 28, at 8:00 a.m. (Eastern Time) to discuss the results of operations for the third quarter. Topics may include forward-looking information, such as the Company’s outlook on future results, trends in operations, and other material information.

The dial-in number for the conference call is (866) 575-6539 for U.S. and Canada (pass code 323905). For international, the dial-in number is (929) 477-0402 (pass code 323905). A live webcast of the call will also be available at www.investors.unum.com in a listen-only mode. It is recommended that webcast viewers access the "Investors" section of the Company’s website and opt-in to the webcast approximately 5-10 minutes prior to the start of the call. A replay of the webcast will be available on the Company’s website. A replay of the call will also be available through Wednesday, November 4 by dialing (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (International) – pass code 323905.

In conjunction with today’s earnings announcement, the Company’s Statistical Supplement for the third quarter of 2020 is available on the "Investors" section of the Company’s website.